Quick access to up-to-date company information.
First U.S. Patients Enroll in Boehringer Ingelheim’s Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)
Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer
Boehringer Ingelheim Statement on Agreement to Sell Roxane to Hikma Pharmaceuticals PLC
Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)
STIOLTO™ RESPIMAT® Now Available in the United States for the Treatment of COPD
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877